The direct reprogramming of somatic cells has immense implications in various areas of medicine. Although remarkable progress has been made in developing novel reprogramming methods, the efficiency and fidelity of reprogramming still need to be improved. Inflammatory bowel disease (IBD) involves chronic inflammatory diseases of the gastrointestinal tract with a complex etiology caused by various genetic, immunological and environmental factors. Recently, the role of stem cells has been proposed in pathogenesis and therapy of IBD. However, the efficiency and the safety of the stem cell treatments depend on the origin of the stem cell and the administration method. We hypothesize that the reprogramming of the intestinal cells into a pluripotent state is of huge importance for IBD therapy and prevention. The vectors carrying reprogramming genes encoding pluripotency factors can be transferred to the damaged tissue, in this case the intestine, by means of invasive bacterial vectors able to colonize colon mucosa. Reconstruction of tissues in vivo might avoid problems encountered in tissue rebuilding in vitro because of lack of appropriate scaffolds and microenvironments. Herein we present a review of recent literature and a perspective of in vivo reprogramming in IBD using bacterial vectors and analyze the rationale for such approach.
A variety of cell types have been reprogrammed so far; however, fibroblasts are still the most commonly used in basic research. Both easy isolation and genetic modification make them the cell type of choice. 1, 2, 8, 9 It has also been shown that some variations on OSKM and alternative factors can be used to successfully reprogram cells. In mouse fibroblasts, Sox1 and Sox3 can replace Sox2, although it decreases the reprogramming efficiency; L-Myc and N-Myc can replace c-Myc, and Klf4 can be substituted with Klf2. 10 Interestingly, c-Myc can be excluded for reprogramming of mouse and human fibroblasts as these cells express c-Myc and Klf4. 11 Removal of this potent mitogen has proven to be essential to prevent the resulting cells in the mouse system from becoming potentially tumorigenic; extrapolating these observations to use of the technique in humans, the avoidance or removal of this transgene will be essential for future clinical applications. Similarly, Eminli et al. 4 have shown that mouse neural progenitor cells do not require overexpression of Sox2 for reprogramming, as they naturally express high levels of endogenous Sox2.
For human fibroblasts it has been reported that a different set of four factors-Oct4, Sox2, Nanog and Lind28-is also suitable for reprogramming. 9 Later, however, Huangfu et al. 12 reported that a small-molecule chemical (valproic acid) can replace some of the transcription factors and that reprogramming of primary human fibroblasts thus only requires Oct4 and Sox2. Another crucial step towards a safe and practical use of reprogrammed cells has been made in a paper by Kim et al. 13 who showed that Oct4 alone was able to convert human neural stem cells into iPS cells. A comprehensive summary of different sets of transcription factors necessary to reprogram somatic cells has recently been published by Miyazaki et al. 14 These results clearly show that the combination of factors necessary for reprogramming of somatic cells into iPS cells is dependent on the chemical environment and the cell type, which is to be reprogrammed.
Moreover, pluripotent stem cells express a distinctive set of microRNAs, which are involved in the regulation of pluripotent stem (PS) cell cycle and influence features such as morphology, epigenetic profile and resistance to apoptosis of PS cells. 15 There is increasing evidence that these molecules have a key role in the regulatory networks of cellular reprogramming.
Initially, retrovirus-mediated gene transduction was used as a strategy for generating iPS cells. 1, 8 Later generations of iPS cells employed lentiviruses with constitutive or inducible expression. [16] [17] [18] Unlike retroviruses, lentiviruses can be produced relatively easily and can infect both dividing and non-dividing cells. Both of these viral systems are very efficient at delivering genes; however, their use has been criticized for their permanent integration into the host genome. 19 The major concern with these viral vectors is the induction of tumorigenesis by means of integration into critical sites of the genome, which can lead to activation of oncogenes. Moreover, the continuous overexpression of pluripotency genes seen after the integration into the genome resembles cancer phenotype, creating concerns about the tumorigenicity of induced pluripotency. In fact, induced pluripotency and oncogenic transformation have been shown to be similar processes. 20 Therefore, new strategies are needed such as the direct application of peptides and recombinant proteins into the host cells. 21, 22 Another potential alternative to the retro-or lentivirusmediated gene transduction is the use of expression plasmids or episomal vectors containing the genes encoding the transcription factors. These vectors represent a reasonable way to avoid integration into the host genome, while providing a similar efficiency of reprogramming. Several studies have shown a successful generation of iPS cells using plasmids 23, 24 or episomal vectors, 23, 24 showing that the reprogramming does not require integration of the transgenes into the host cell genome or the permanent presence of the reprogramming factors. These techniques, however, do not represent the gold standard for the experimental studies on cell reprogramming. Although remarkable progress has been made in developing novel reprogramming methods, the efficiency and fidelity of reprogramming need to be improved in order to increase the experimental and translational utility of reprogrammed cells.
Apart from the standard genetic reprogramming techniques, the possibility of reprogramming using small-molecule chemicals brings new light into the research. It has been found that small molecules can inhibit some of the key differentiation-inducing pathways. 25 Several small-molecule compounds have already been successfully tested as a replacement for the delivery of some of the genes encoding transcription factors. 12, 26, 27 These chemical compounds can significantly improve the efficiency and safety of reprogramming and thus potentially bring it near the clinical setting.
Currently, mouse iPS cells meet all the standard criteria for being declared pluripotent in terms of developmental potential. These include the ability to differentiate in vitro into all three germ layers, formation of teratomas, formation of chimeras, germline transmission and tetraploid complementation. 28 Generation of a whole animal through complementation with a tetraploid embryo was independently first achieved by Kang's and Zhao's groups. 29, 30 Success in an even more rigorous test of full reprogramming was reported several years ago. In two reports, mouse iPS cells transplanted into tetraploid embryos were able to generate live mice. 31, 32 In the early studies on reprogramming, mouse iPS cells were selected via the Fbx15 gene. Cells were not fully reprogrammed, as they could form only teratomas. 1 However, the subsequent studies successfully demonstrated the generation of chimeric mice with germline transmission ability. 33, 34 Moreover, at a molecular level, iPS cells must display specific gene expression profiles. Mouse pluripotency markers that are activated during mouse iPS cell derivation have been shown to be alkaline phosphatase, which is activated first, followed by stage-specific embryonic antigen 1. Also, Nanog and the endogenous Oct4 gene mark fully reprogrammed cells. However, expression of these two genes was only observed late in the process. 17 In human cells, the marker of pluripotency is the expression of the surface antigens SSEA-3, SSEA-4, Tra-1-60 and Tra-1-81, and the intracellular factors Nanog, Oct4, Klf4 and Sox2. Comprehensive step-by-step protocols cells have recently been published for the generation 23, 35 and detailed characterization 36 of iPS cells.
APPLICATIONS
With the discovery of the reprogramming ability of somatic cells, new possibilities appeared in medical research. The most discussed purpose of iPS cells is the potential application in regenerative medicine. Advantages of this technology would be the transplantation of a lineage-restricted progenitor cell, derived from a patient-specific iPS cell that does not trigger any immune response, does not promote tumor formation and that could recover the target tissue. 37 Nowadays, the developed world health status is characterized by a high prevalence of chronic disorders, such as the cardiovascular and metabolic diseases. Given that a difficulty in modeling human diseases is evident in laboratory assays or experimental animals, new approaches are on the horizon. iPS cells isolated directly from the patient may represent a new avenue in the drug discovery research. 38 Reprogrammed somatic cells from patients have already been applied in disease modeling, drug testing and disease-specific drug discovery. 39 All these applications hold great promise in the therapy of neurodegenerative disorders, such as Alzheimer's and Huntington's disease, in reproductive technology, or in the treatment of monogenic disease such as cystic fibrosis and sickle cell anemia. [40] [41] [42] However, the potential of iPS cells seems to be predominantly in regenerative medicine, and has already been proposed in cardiac repair, 43 ischemic stroke, 44 various neurological diseases 45 and diabetes. 46 Stem cellmediated therapy has also been proposed as a potential therapy for chronic diseases of a complex etiopathogenesis such as inflammatory bowel disease (IBD), although only the hematopoietic stem cells, 47, 48 mesenchymal stem cells (MSCs) 49, 50 and colonic stem cells 51 have been tested so far. Nevertheless, this makes the possible spectrum of iPS cells application even wider and provides a rationale for the use of iPS cells in IBD.
INFLAMMATORY BOWEL DISEASE
IBD is a term describing chronic inflammatory diseases of the gastrointestinal tract with a complex etiology caused by various genetic, immunological and environmental factors. Since the early 1950s, there has been a steep increase in the incidence of IBD in the western world. 52 IBD is more common in the developed world than in the developing world. At present, IBD affects 0.5-1.0% of the western European population. The highest rates are reported from Scandinavia, Scotland, England and also from North America. In Central and Southern Europe, IBD seems to be less common, and rare in developing countries. 53 IBD refers to ulcerative colitis (UC) and Crohn's disease (CD), which are diseases of the digestive tract with similar clinical, pathological and epidemiological features. The inflammatory process of UC primarily affects the mucosa and submucosa of the large intestine and rectum. Classic symptoms of UC are diarrhea, tenesmus, hematochezia and defecatory urgency. Unlike UC, virtually any part of the gastrointestinal tract can be affected by CD. However, intestinal inflammation in CD most frequently involves the terminal ileum and colon. Symptoms of CD are abdominal pain, weight loss and diarrhea. 54 Extraintestinal manifestations of IBD may affect joints, eyes and/or the skin. In IBD, remitting and relapsing conditions alternate in both UC and CD, and despite medical therapy surgical intervention is frequently required. 55 The basic hallmarks of both diseases on a tissue level are depicted on Figure 1 .
The etiology of both CD and UC still remains unclear. Therefore, in recent years, IBD-related animal models were developed to study the possible factors involved in the disease pathophysiological mechanisms. Among them, chemically induced models of intestinal inflammation, such as trinitrobenzene sulfonic acid, oxazolone and dextran sulfate sodium (DSS) colitis, belong to the most commonly used IBD animal models. 56 Despite their limitations, they resemble in some important immunological and histopathological aspects IBD in humans. These include extensive cellular infiltrates, submucosal edema and epithelial erosion seen in active DSS-induced colitis. 57 However, as the main pathogenic factor is the chemical destruction of the mucosa, they lack other initiating factors, such as genetics, innate immune response and microbiota, and therefore are more suitable for studying acute colitis events. In addition, unlike in human colitis the presence of
In vivo reprogramming in colitis
A Wagnerova and R Gardlik T cells or B cells are not required for acute DSS-induced colitis in mice. 58 Histological progression of the mouse colon tissue from healthy state to active colitis is shown on Figure 2 .
The conventional therapies for chronic IBD consist mainly of immunological, genetic and drug-based approaches. The most common drug treatment includes corticosteroids, sulfasalazine or salicylates (mesalazine or olsalazine). Other modalities include immunosuppressive agents (for example, azathioprine, 6-mercaptopurine, methotrexate and cyclosporine), antibiotics (for example, metronidazole) and biological agents (for example, infliximab). [59] [60] [61] However, this approach is symptom-oriented and systemic administration of drugs increases the potential for harmful side effects. Besides costly drugs, during relapse the patients require intensive treatment, including invasive investigations and surgery, for example, intestinal resection. Consequently, patients with IBD are considered expensive to manage. 62 Considering the multifactorial pathogenesis of IBD (genetic, immunological and environmental), treatment depends on the type, severity and extent of the disease. As mentioned above, the most common treatment of IBD consists of drug administration and surgical interventions, which could result in severe side effects. This fact encourages the urgent need of new insight into the treatment possibilities. The hypothesis that intestinal bacteria have a role in the pathogenesis of IBD presents a potential method to reduce the bowel inflammation. 63 In a series of studies, intestinal microbiota manipulation via the administration of probiotics has been used in the treatment of IBD. [64] [65] [66] Another option is the use of prebiotics to increase the numbers of beneficial endogenous bacterial strains. 67, 68 In the last few decades, bacteria-mediated gene therapy has attracted the interest of researchers due to its wide applications. Palffy et al. 69, 70 used an approach called bactofection in their study. They analyzed the effects of salmonella-mediated gene therapy using attenuated bacteria Salmonella typhimurium SL7207 carrying plasmids with genes for SOD1 and 7ND genes in DSS-induced colitis. Results showed that the salmonella-mediated antioxidative and anti-inflammatory gene therapy is able to ameliorate colitis in both mice and rats. 69, 70 Also under active investigation is stem cell therapy and its use in IBD. It has been proved in several experimental studies in rodents. In mouse model of IBD, a non-myeloablative adult stem cell therapy (that is, without ablation of bone marrow) allowed for an improved microcirculation and enhanced tissue repair. 71 This study clearly provided a rationale for stem cell-based therapy of mouse models of IBD. Hematopoietic stem cells used in this study are considered to act through repopulation of the immune system and reset of the immunological response to antigens in the gut lumen. Next, MSCs derived from either bone marrow or adipose tissue also seem to be a promising tool in IBD treatment due to their immunosuppressive and tissue repair properties. 72 However, available data show contradictory results in the use of various MSCs. A highly effective treatment of murine colitis has been reported using human adipose-derived MSCs, 49 and human umbilical cord-derived MSCs. 50 In contrast, colitogenic properties of bone marrow MSCs were demonstrated, as they formed the niche for colitogenic CD4 þ memory T cells in bone marrow. 73 The source of the MSCs seems to be one of the key reasons for these opposing results. Unlike the majority of studies that use systemic (that is, intravascular) administration of stem cells, which may be associated with many side effects, Zhou et al. 51 investigated if local application of adult colonic stem cells (CSCs) can increase mucosal repair. After the successful local infusion of CSCs, local inflammatory cytokines and the epithelial barrier were improved with only minimal effects on the innate immune system. Further, an interesting hypothesis has been outlined, in which the authors propose that even neural stem cells may ameliorate IBD through inhibiting immune responses and enhancement of neural cell regeneration in intestinal mucosa. 74 Taken together, the efficiency and the safety of the stem cell treatments highly depend on the origin of the stem cell and the administration method.
The human studies published so far focused on hematopoietic stem cell transplantation. Both autologous (from the patients themselves) and allogenic (from a matching donor) hematopoietic stem cell transplantation was proven to be an effective treatment for IBD patients. 47, 48, 75, 76 However, these reports are based on small number of patients and provide only preliminary data. Thus, more clinical studies are needed to fully uncover the potential of stem cell therapy in human IBD. Although several positive results have already been reported using stem cells from various sources for therapy of IBD, both in animals and patients, the iPS cells prepared by reprogramming have not yet been tested for this purpose. In vivo reprogramming in colitis A Wagnerova and R Gardlik PERSPECTIVE Considering the knowledge about iPS cells and the nature of IBD, we hypothesize that the reprogramming of the intestinal cells into a pluripotent state is of huge importance for IBD therapy and prevention. Our theory is based on the presumption that the adult somatic cells able to return to the pluripotent state by exposure to some factors (chemical, immunological) have the ability to differentiate into the desired cell phenotype resistant to stimuli that could lead to IBD development.
In ex vivo reprogramming, the patient's somatic cells are isolated, reprogrammed and implanted back into the patient. This, however, requires a spectrum of biochemical, molecular and immunological tests to ensure the reprogrammed cells fulfill the criteria necessary for therapeutic applications. Thus, this approach might be technically challenging, time consuming and eventually costly. Also the systemic delivery of the reprogrammed cells can be associated with a higher risk of adverse events, such as unwanted immune reaction or homing of the cells in non-target tissues leading to insufficient therapeutic outcome. In contrast, in in vivo reprogramming, the vectors carrying reprogramming genes encoding pluripotency factors are transferred to the damaged tissue, in this case the intestine. This can be achieved by means of invasive bacterial vectors able to colonize colon mucosa. We assume this method to be more realistic due to the possibility of application of the natural gut microbiota and no need of surgical intervention. The idea is that the gut microbiota can be isolated, genetically modified to carry and deliver pluripotency genes and eventually administered back into the natural environment in the gut.
Although a number of studies focus on ex vivo gene therapy dealing with the difficulties and possible side effects, [77] [78] [79] [80] [81] [82] little is known about the in vivo induction of pluripotency. One of the main problems regarding the in vivo environment is the variety of cells forming the tissue, as only a portion of tissue cells are suitable for transforming. Further, partial and off-target reprogramming of cells needs to be taken into account. However, the most notable setback is the somatic tumor formation. To overcome these issues thorough reprogramming protocol-optimizations are required.
Recently, novel strategies have been described for the therapeutic use of human pluripotent stem cells including iPS cells via the generation of specific cell types, including those of endodermal lineage such as the liver, pancreatic and intestinal cells. 83 A novel protocol for the direct generation of intestinal tissue from human embryonic stem cells and iPS cells has been published. 84 The authors were able to mimic embryonic development of the intestine by performing growth factor manipulations in vitro. Thus, iPS cells differentiated into a complex three-dimensional intestinal tissue with the columnar epithelium organized into villus-like structures with crypt-like zones. The formed tissue seemed to be fully functional, as it actually contained enterocytes, goblet cells, Paneth cells and enteroendocrine cells. The fact that the ex vivo formed iPS cells can give rise to intestinal tissue indicates that a similar process might take place in in vivo setting. Bacterial microflora represents a powerful tool for delivery of reprogramming factors or genes directly to intestinal cells, as it naturally colonizes the gut and is in direct contact with the target cells. Thus, generation of the intestinal stem cells in vivo by means of bacteria-mediated gene delivery has the potential to be effective in terms of generating fully functional intestinal tissue.
ISSUES AND VARIOUS ASPECTS
As the limitations and drawbacks of iPS cells have been studied in detail for years, a number of issues would be predictable reprogramming cells in vivo. Just to name the most prominent and serious problems that might potentially arise from direct in vivo reprogramming: partial reprogramming of certain subset of cells; different reprogramming rate of cells; reprogramming of off-target cells in the body; formation of tumors; and need for reprogramming cells that are refractory to reprogramming. These, however, could be theoretically overcome by employing appropriate molecular tools. For example, the expression of extracellular proteins on the surface of the bacterial vectors (for example, invasin in Yersinia species) that are specific for target cells (M-cells expressing beta1 integrin receptors) might prevent delivery of the reprogramming genes into other cells, which can minimize the chance of off-target reprogramming. In addition, compliance with strict therapeutic conditions such as specific pre-treatment of the gut might help to standardize the environment in which the reprogramming is to take place and thus help to overcome some of the problems listed above such as the refractoriness of certain cells or the formation of target cell subpopulations.
It is believed that the reprogramming frequency depends on the differentiation status of the target cells. It has been shown that iPS cells generated from different somatic cell origins have different differentiation properties. 85 The reprogrammed state and differentiation potential of the generated iPS cells may vary even using the same reprogramming protocol. 86 It seems that some of the cells that are being reprogrammed remain stuck in certain stage of reprogramming with a weak differentiation potential. The reason for this observation is unclear, but likely has something to do with a stochastic nature of the process. 87 Therefore, a similar phenomenon will likely be seen during and after in vivo reprogramming. In addition, when delivering the reprogramming genes into the target cells, high efficiency of transfection is extremely important for efficient reprogramming. Therefore, it remains to be explored whether transfecting only a subset of easily accessible cells in the tissue can provide sufficient therapeutic outcome. 88 Analogous to ex vivo reprogramming, stringent methods have to be employed for in vivo methods to prove the pluripotency of transfected cells. Reaching a sufficient proportion of fully reprogrammed cells in the target tissue can be problematic, as only a portion of the tissue cells are accessible to transfect. This, however, depends on the method and specificity of delivery, as well as the nature of the target cells. Rigorous testing on small animals with thorough histological and molecular analysis should uncover any possible efficiency issues. Ultimately, the primary outcome of the in vivo reprogramming would be the clinical benefit. An important question to focus on, specifically for in vivo studies, is whether it is necessary in all cases to reprogram cells back to a pluripotent stem cell state. It may be sufficient to reprogram the cells to a state of adult stem cell that could be more closely related to the cell type needed for cell replacement therapy. 88 Although many hurdles remain to be overcome, reconstruction of tissues in vivo might avoid problems encountered in tissue rebuilding in vitro because of lack of appropriate scaffolds and microenvironments. It is possible that in vivo reconstruction might lead to tissue repair that more accurately reproduces the structure and function of the endogenous tissue. In the future, one might foresee that it could ultimately become possible to interconvert tissue types instead of individual cells.
BACTERIA-MEDIATED REPROGRAMMING
In gastrointestinal diseases such as IBD, bacteria could be an ideal vector to deliver the genes. Moreover, together with the achievements in genetic engineering of strains with reduced virulence, genetically modified natural gut bacteria appear to be the most rational way. The intestinal mucosa cells have an important role in the pathogenesis of IBD and have an enormous
In vivo reprogramming in colitis A Wagnerova and R Gardlik renewal capacity, thus, this fact provides significant conditions favorable for the therapeutic application of in vivo reprogramming. Therefore, intestinal stem cells, crucial for the renewal of the intestinal epithelium, together with the functional normal cells could give a hand in the restoration of the damaged tissue to healthy and differentiated cells. The cells of the intestinal mucosa or other type of cells of the intestinal wall may, by molecular reprogramming, reach a state of resistance to adverse inflammatory events and ultimately give rise to new healthy and fully functional tissue. There is no available literature on reprogramming intestinal cells that could support this hypothesis. However, several previous studies suggest that the cells generated from iPS cells could have different characteristics than the parental cells in terms of resistance to various stimuli. This has been seen on iPS cells-derived cardiomyocytes that were less sensitive to tetrodotoxin 89 and iPS cells-derived MSCs that were more resistant to preactivated NK-cells than the bone marrow-derived MSCs. 90 In addition, adult chimeric mice engineered by transplantation of stem cells into blastocyst were resistant to myocardial infarction induced by coronary occlusion. 91 This finding suggests that also a pre-emptive stem cell therapy might lead to a protective phenotype later when the damaging event occurs.
As vectors to transfer therapeutic sequences into cells of target intestinal tissues, bacteria can be used that are able to penetrate into the cells and provide them with a therapeutic plasmid (bactofection). In previous studies, our research group has demonstrated validity and effectiveness of bactofection in IBD in rats 69 as well as in mice. 70 The principle of bacteria-mediated gene delivery has been described previously 92 and is shown on Figure 3 .
Bacteria as vectors in gene therapy have been known for a long time and have a wide range of action and a spectrum of uses. 93 Currently available strains are genetically modified to have reduced and strictly defined virulence, which allows them to enter the cells in the target tissue while maintaining safe conditions. Bacterial vectors are especially appropriate for IBD therapy thanks to their natural ability to persist in the intestinal microflora. Such bacterial therapy of IBD was first successfully applied more than a decade ago, when the bacteria Lactococcus lactis secreting interleukin-10 was administered in murine colitis. 65 Since then, many other studies have confirmed the validity of the bacterial approach in IBD using different combinations of vector and therapeutic gene. 69, 70, [94] [95] [96] [97] Despite the broad application of bacterial gene therapy, bacteria have not yet been used to reprogram cells in IBD, or in other conditions.
Recently, a work was published in which the authors describe the possibility of reprogramming human fibroblasts by lactic acid bacteria Lactobacillus acidophilus (JCM 1021). 98 The applied bacteria entered the intracellular environment via a previously unknown mechanism and caused formation of embryoid bodies, which exhibited characteristics of multipotency, which was proved by various in vitro and in vivo assays. The bacteria used in this study, however, did not bear any therapeutic gene designed for bactofection to target cells and their effect was thus associated with their natural properties. Moreover, the resulting multipotent cells were characterized by slightly different properties (different expression of pluripotency markers) compared with standard iPS cells that are mostly created by overexpression of the four Yamanaka factors. However, the authors emphasize the potential of bacterial vectors for induction of pluripotency in the intestine, where many types of bacteria are present that provide benefit in various pathological conditions and through different molecular mechanisms. One of these mechanisms could be reprogramming of cells in the intestinal wall into the state of pluripotency and subsequent differentiation into a phenotype resistant to pathological factors causing the disease.
Whereas some knowledge exists on the differentiation of iPS cells into intestinal cells, 84, 99 little is known about specific conditions that might be required to efficiently reprogram intestinal cells into pluripotent state. Generation of iPS cells from intestinal somatic cells has not been reported so far. Thus, unless some new data arise, the future studies will have to rely on the results from studies on different cell lineages, as described in Reprogramming section of this article. However, a recent study has described the conversion of gastric epithelial cells into intestinal stem-like cells using the stemness-associated reprogramming factors SALL4 and KLF5. 100 Therefore, a subset of related factors might theoretically represent good candidates for therapeutic genes that are to be delivered into intestinal cells by transgenic bacterial vectors.
The primary knowledge on safety and efficiency of the proposed approach will most likely come from studies on small animals and will require thorough molecular and histological testing. In case of use in humans a battery of clinical tests should be performed to verify that the intestinal reprogramming is proceeding safely and efficiently. Pilot studies should focus on distribution and survival of the applied bacteria in the intestine, along with adverse events that might be associated with administration of the transgenic bacteria. As the bacterial vectors invade the cells, it would be also useful to check for the presence of bacteria in the blood. Biochemical measurement of inflammatory parameters and cytometric characterization of activated immune cells would provide some picture on systemic safety of this approach. Detection of blood cells expressing stemnessassociated markers using flow cytometry would show if the reprogramming process is strictly localized or spreading.
Next, invasive procedures would be required to analyze the efficiency of the intestinal cell reprogramming. A detailed visual examination of the intestinal mucosa during colonoscopy will provide a basic knowledge about the therapeutic outcome and possible adverse events on an organ level. To achieve a more detailed picture of the molecular processes in the intestine, the samples from intestinal biopsy will be taken for molecular and histological analyses. These would also uncover the potential healing process on a tissue level. Last but not the least, the isolation of the intestinal cells expressing the factors of pluripotency and their qualitative and quantitative characterization could help to verify the efficiency of the intestinal reprogramming. In vivo reprogramming in colitis A Wagnerova and R Gardlik CONCLUDING REMARKS All previously published papers so far have dealt with influencing target cells ex vivo and their subsequent reimplanting into the body. Despite the still low efficiency of reprogramming cells by transfer of genes encoding reprogramming factors in vitro, our hypothesis says that the in vivo approach can provide a benefit by direct delivery of DNA-encoding reprogramming factors into the target tissue or organ. Target cells that are to be reprogrammed are transduced in their natural environment, which provides all the necessary molecular and spatial factors that are absent in ex vivo reprogramming. The advantages of this approach include the circumvention of the strict conditions necessary for cell culture studies dealing with iPS cells. To verify this concept, it is necessary to perform a series of pilot experiments focused primarily on the safety of such an approach. Unlike standard ex vivo methods with a number of research and practical applications, creating iPS cells in vivo would likely provide benefit almost exclusively for therapeutic purposes. Currently, there are modern methods available to improve safety, specificity and cell targeting of in vivo gene therapy.
As there is no available literature concerning in-vivo-induced pluripotency, it is difficult to predict how the cells will react to the treatment and whether the reprogramming efficiency will provide any promising results. Therefore, long-term experiments are needed to be performed to study the side effects and safety of the method in detail.
The enormous renewal capacity of the intestinal epithelium has made the intestine one of the favorite tissues in which to study stem cell regulation and, thus, also the therapeutic application of in vivo reprogramming. Homeostasis of the intestinal epithelium is maintained by intestinal stem cells that reside at the bottom of the crypts. These intestinal stem cells are crucial for the renewal of the differentiated progeny within the intestinal layer. Given that the degeneration of intestinal mucosal cells has an essential role in pathogenesis of IBD, therapy based on their reprogramming provides a rationale for the escape of these cells from the harmful effects and thus prevention of damage in IBD. If the reprogramming is successful, the surrounding normal cells in the intestine will provide the factors and environment necessary for the return to a fully differentiated and functional state. It seems that reprogramming processes might take place in the intestine after in vivo gene delivery, even though very low transfection and reprogramming efficiencies would be expected.
Herein we present a hypothesis of bacterially mediated in vivo reprogramming for therapeutic purposes. To fully evaluate the concept and further evolve the perspective, it is crucial to perform a number of preliminary experiments on safety.
